Anti-tumor mechanism of lactoferrin

doi:10.3760/cma.j.issn.1673-422X.2019.05.007

Abstract

Abstract: Alterations of the lactoferrin gene are associated with an increased incidence of tumor, however, the exact mechanisms involved in the antitumor activity of lactoferrin are still unclear. Several studies suggest that lactoferrin can affect the initiation and development of tumors via different mechanisms such as damaging cell membranes, inducing apoptosis, blocking cell cycle, regulating cellular immune response and inhibiting angiogenesis in different cancer cell lines. Further study about the mechanism can provide new ideas for clinical prevention and treatment of tumors.

Key words: Lactoferrin, Neoplasms, Apoptosis

Mo Xiaomei, Qin Pengfei, Zhao Na, Yan Meixing, Xu Lujie. Anti-tumor mechanism of lactoferrin[J]. Journal of International Oncology, 2019, 46(5): 285-288.

References

［1］ Hao L, Shan Q, Wei J, et al. Lactoferrin: major physiological functions and applications［J］. Curr Protein Pept Sci, 2019, 20(2): 139-144. DOI: 10.2174/1389203719666180514150921. ［2］ Zhang Y, Lima CF, Rodrigues LR. Anticancer effects of lactoferrin: underlying mechanisms and future trends in cancer therapy［J］. Nutr Rev, 2014, 72(12): 763-773. DOI: 10.1111/nure.12155. ［3］ Zhang J, Ling T, Wu H, et al. Reexpression of lactotransferrin, a candidate tumor suppressor inactivated by promoter hypermethylation, impairs the malignance of oral squamous cell carcinoma cells［J］. J Oral Pathol Med, 2015, 44(8): 578-584. DOI: 10.1111/jop.12279. ［4］ Zadvornyi TV, Lukianova NY, Borikun TV, et al. Effects of exogenous lactoferrin on phenotypic profile and invasiveness of human prostate cancer cells (DU145 and LNCaP) in vitro［J］. Exp Oncol, 2018, 40(3): 184-189. ［5］ Furmanski P, Li ZP, Fortuna MB, et al. Multiple molecular forms of human lactoferrin. Identification of a class of lactoferrins that possess ribonuclease activity and lack ironbinding capacity［J］. J Exp Med, 1989, 170(2): 415-429. DOI: 10.1084/jem.170.2.415. ［6］ Kanwar JR, Mahidhara G, Sasidharan S, et al. FebLf nanoformulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc［J］. Nanomedicine(Lond), 2015, 10(1): 35-55. DOI: 10.2217/nnm.14.132. ［7］ Sanchez CJ, Le Treut T, Boehrer A, et al. Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity［J］. Cancer Immunol Immunother, 2011, 60(1): 1-13. DOI: 10.1007/s00262-010-0898-x. ［8］ Riedl S, Rinner B, Schaider H, et al. Killing of melanoma cells and their metastases by human lactoferricin derivatives requires interaction with the cancer marker phosphatidylserine［J］. Biometals, 2014, 27(5): 981-997. DOI: 10.1007/s10534-014-9749-0. ［9］ Riedl S, Leber R, Rinner B, et al. Human lactoferricin derived dipeptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserine［J］. Biochimica Biophysica Acta, 2015, 1848(11 Pt A): 2918-2931. DOI: 10.1016/j.bbamem.2015.07.018. ［10］ Camilio KA, Berge G, Ravuri CS, et al. Complete regression and systemic protective immune responses obtained in b16 melanomas after treatment with LTX-315［J］. Cancer Immunol Immunother, 2014, 63(6): 601-613.DOI: 10.1007/s00262-014-1540-0. ［11］ Sheng M, Zhao Y, Zhang A, et al. The effect of LfcinB9 on human ovarian cancer cell SKOV-3 is mediated by inducing apoptosis［J］. J Pept Sci, 2014, 20(10): 803-810. DOI: 10.1002/psc.2670. ［12］ Gibbons JA, Kanwar JR, Kanwar RK. Ironfree and ironsaturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer［J］. BMC Cancer, 2015, 15: 425. DOI: 10.1186/s12885-015-1441-4. ［13］ Wang S, Tu J, Zhou C, et al. The effect of Lfcin-B on non-small cell lung cancer H460 cells is mediated by inhibiting VEGF expression and inducing apoptosis［J］. Arch Pharm Res, 2015, 38(2): 261-271. DOI: 10.1007/s12272-014-0373-x. ［14］ Deng M, Zhang W, Tang H, et al. Lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing AKT through multiple mechanisms［J］. Oncogene, 2013, 32(36): 4273-4283. DOI: 10.1038/onc.2012.434. ［15］ Luzi C, Brisdelli F, Iorio R, et al. Apoptotic effects of bovine apolactoferrin on HeLa tumor cells［J］. Cell Biochem Funct, 2017, 35(1): 33-41. DOI: 10.1002/cbf.3242. ［16］ Chea C, Miyauchi M, Inubushi T, et al. Molecular mechanism of inhibitory effects of bovine lactoferrin on the growth of oral squamous cell carcinoma［J］. PLoS One, 2018, 13(1): e0191683. DOI: 10.1371/journal.pone.0191683. ［17］ Jiang R, Lnnerdal B. Bovine lactoferrin and lactoferricin exert antitumor activities on human colorectal cancer cells (HT-29) by activating various signaling pathways［J］. Biochem Cell Biol, 2017, 95(1): 99-109. DOI: 10.1139/bcb-2016-0094. ［18］ Zhang Y, Nicolau A, Lima CF, et al. Bovine lactoferrin induces cell cycle arrest and inhibits mTOR signaling in breast cancer cells［J］. Nutr Cancer, 2014, 66 (8): 1371-1385. DOI: 10.1080/01635581.2014.956260. ［19］ Arcella A, Oliva MA, Staffieri S, et al. In vitro and in vivo effect of human lactoferrin on glioblastoma growth［J］. J Neurosurg, 2015, 123(4): 1026-1035. DOI: 10.3171/2014.12. ［20］ Kanwar JR, Palmano KP, Sun X, et al. ‘Ironsaturated’ lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy［J］. Immunol Cell Biol, 2008, 86(3): 277-288. DOI: 10.1038/sj.icb.7100163. ［21］ Li HY, Li M, Luo CC, et al. Lactoferrin exerts antitumor effects by inhibiting angiogenesis in a HT29 human colon tumor model［J］. J Agric Food Chem, 2017, 65(48): 10464-10472. DOI: 10.1021/acs.jafc.7b03390. ［22］ Pereira CS, Guedes JP, Gonalves M, et al. Lactoferrin selectively triggers apoptosis in highly metastatic breast cancer cells through inhibition of plasmalemmal VH⁺ ATPase［J］. Oncotarget, 2016, 7(38): 6214462158. DOI: 10.18632/oncotarget.11394. ［23］ Guedes JP, Pereira CS, Rodrigues LR, et al. Bovine milk lactoferrin selectively kills highly metastatic prostate cancer PC-3 and osteosarcoma MG-63 cells in vitro［J］. Front Oncol, 2018, 8: 200. DOI: 10.3389/fonc.2018.00200. ［24］ Shankaranarayanan JS, Kanwar JR, AI-Juhaishi AJ, et al. Doxorubicin conjugated to immunomodulatory anticancer lactoferrin displays improved cytotoxicity overcoming prostate cancer chemo resistance and inhibits tumour development in TRAMP mice［J］. Sci Rep, 2016, 6: 32062. DOI: 10.1038/srep32062. ［25］ Chekhun VF, Zalutskii IV, Naleskina LA, et al. Modifying effects of lactoferrin in vitro on molecular phenotype of human breast cancer cells［J］. Exp Oncol, 2015, 37(3): 181-186. ［26］ Wang A, Duncan SE, Lesser GJ, et al. Effect of lactoferrin on taste and smell abnormalities induced by chemotherapy: a proteome analysis［J］. Food Funct, 2018, 9(9): 4948-4958. DOI: 10.1039/c8fo00813b. ［27］ Roseanu A, Florian PE, Moisei M, et al. Liposomalization of lactoferrin enhanced its antitumoral effects on melanoma cells［J］. Biometals, 2010, 23(3): 485-492. DOI: 10.1007/s10534-010-9312-6. ［28］ Roy K, Patel YS, Kanwar RK, et al. Biodegradable Eri silk nanoparticles as a delivery vehicle for bovine lactoferrin against MDA-MB-231 and MCF-7 breast cancer cells［J］. Int J Nanomedicine, 2015, 11: 25-44. DOI: 10.2147/IJN.S91810. ［29］ Lin LY, Koh PY, Somani S, et al. Tumor regression following intravenous administration of lactoferrin and lactoferricinbearing dendriplexes［J］. Nanomedicine, 2015, 11(6): 1445-1454. DOI: 10.1016/j.nano.2015.04.006.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.